RUNX1 and acute myeloid leukemia: In this context, recent evaluations of the antileukemic properties of HDACis in t(8;21) AML revealed the promotion of terminal myeloid differentiation through HDACi-induced AML1/ETO9a FP proteasomal degradation [171].